Atrial fibrillation (AF) occurs approximately in 3% of general population, with greater prevalence in elderly. Non-vitamin K-dependent oral anticoagulant agents (NOACs) according to the current European guidelines are recommended for patients with AF at high risk for stroke as a first-choice treatment. NOACs are not inferior to warfarin or some of them are better than warfarin in reducing the rate of ischemic stroke. Moreover, they significantly reduce the rate of intracranial hemorrhages, major bleedings, and mortality compared with warfarin. Nevertheless according to ESC guidelines, NOACs are not recommended in patients with creatinine clearance < 30 mL/min. Observational studies provide contradictive data. Only few new trials are ongoing. Therefore, it is not clear if NOACs should be in the future prescribed to patients with advanced CKD and those on dialysis. Moreover, the risk of stroke and bleeding is much higher in such population than in patients without end-stage renal disease (ESRD). The authors provide data on pros and cons of use of NOACs in ESRD patients with AF.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11255-018-1877-y | DOI Listing |
Gen Thorac Cardiovasc Surg Cases
January 2025
Department of Surgery II, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Background: With advancements in minimally invasive thoracic surgery techniques, such as video-assisted thoracoscopic surgery and robotic surgery, the design of vascular staplers has evolved to meet the requirements of these procedures. Consequently, newer generations of automatic staplers with improved handling and reduced size have been introduced, such as two-row staplers, which are more maneuverable and less bulky than their three-row counterparts.
Case Presentation: A 68-year-old man with lung cancer underwent a right middle and lower lobectomy due to tumor invasion into the central middle bronchial trunk, rendering the preservation of the middle lobe impossible.
Am J Hypertens
January 2025
Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University; Xuzhou 221004, China.
Background: Polo-like kinase 2 (PLK2) is associated with cardiac fibrosis in patients with atrial fibrillation. However, the role of PLK2 in sepsis-induced cardiac injury has not been fully elucidated. We hypothesize that PLK2 may participate in the progression of sepsis-induced cardiac injury.
View Article and Find Full Text PDFJ Complement Integr Med
January 2025
Mostafa Khomeini Cardiovascular and Research Hospital, Ilam University of Medical Sciences, Ilam, Iran.
Background And Objectives: Cardiovascular Diseases (CVDs), including Acute Coronary Syndrome (ACS), represent a major global health challenge. Arrhythmias such as Ventricular Tachycardia (VT), Ventricular Fibrillation (VF), Atrial Fibrillation (AF), Premature Ventricular Contractions (PVCs), and Premature Atrial Contractions (PACs) frequently complicate ACS, needing effective management strategies. Omega-3 fatty acids have shown potency in preventing sudden cardiac death by modulating arrhythmias, but their acute effects in ACS patients remain controversial.
View Article and Find Full Text PDFThorac Cancer
January 2025
Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, Iowa, US.
This illustrates the outcomes of patients with esophageal cancer undergoing neoadjuvant concurrent chemoradiation and esophagectomy, specifically focusing on those who develop new-onset atrial fibrillation (NOAF). Statistically significant findings (p < 0.05, dark red) increased mortality and ventricular fibrillation, as well as trends of (p > 0.
View Article and Find Full Text PDFBMJ
January 2025
Department of Population Health Sciences, University of Utah, Salt Lake City VA Informatics, Decision-Enhancement and Analytic Sciences, Salt Lake City, UT, USA.
Objective: To evaluate the effectiveness of multiple decision aid strategies in promoting high quality shared decision making for prevention of stroke in patients with non-valvular atrial fibrillation.
Design: Cluster randomized controlled trial.
Setting: Six academic medical centers in the United States.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!